More recently, SLAB51 has been reported to inhibit cholesterol biosynthesis, reduce the ω-6/ω-3 fatty acid ratio, and attenuate neuroinflammation and oxidative stress, collectively leading to decreased aggregation of Aβ and tau proteins and slowing AD progression [254]. This evidence concerns the gene MAPT and Alzheimer disease.